The H275Y neuraminidase mutation conferring oseltamivir resistance has been reported in several pandemic A/H1N1 (pH1N1) isolates. We sought to evaluate transmission of this mutant virus through the direct contact and the airborne (aerosol and droplet) routes in the ferret model.
Methods
Groups of four ferrets were infected with either wild-type (WT) or oseltamivir-resistant pH1N1 (H275Y) strains. At 24 h following viral infection, a receptive ferret was introduced in the same cage as the infected animal to assess direct contact transmission. For the airborne transmission, naive ferrets were placed in a modified separate cage adjacent to that of their respective index ferret.
Results
The H275Y mutant virus was as efficiently transmitted as the WT strain by direct contact, as 100% (4/4) of contact ferrets in both groups seroconverted and shed virus. Mean peak viral titres were similar in both groups (4x104 and 2.63x104 plaque-forming units/ml after WT or H275Y mutant virus transmission, respectively). Peak viral shedding occurred on day 2 post-contact for the WT group and on day 4 post-contact for the H275Y mutant group. By contrast, airborne transmission of the mutant strain was less efficient, as only 25% (1/4) of contact ferrets seroconverted and shed virus, whereas 100% (4/4) of the WT ferrets did. Peak of viral replication was delayed compared to direct contact transmission and occurred on day 4 post-contact.
Conclusions
Transmission of the H275Y pH1N1 mutant strain by the airborne route is somewhat compromised, which may limit its widespread dissemination.
References
1.
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med2009; 360: 2605–2615.
2.
AbedY., BoivinG.Treatment of respiratory virus infections. Antiviral Res2006; 70: 1–16.
3.
BazM., AbedY., PapenburgJ., BouhyX., HamelinM.E., BoivinG.Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med2009; 361: 2296–2297.
4.
HerlocherM.L., TrusconR., EliasS.Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis2004; 190: 1627–1630.
5.
IvesJ.A., CarrJ.A., MendelD.B.The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res2002; 55: 307–317.
6.
BazM., AbedY., SimonP., HamelinM.E., BoivinG.Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis2010; 201: 740–745.
7.
HamelinM.E., BazM., AbedY.Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog2010; 6: e1001015.
8.
HurtA.C., Nor'eS.S., McCawJ.M.Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets using a competitive mixtures model. J Virol2010; 84: 9427–9438.
9.
BloomJ.D., GongL.I., BaltimoreD.Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science2010; 328: 1272–1275.
10.
DuanS., BoltzD.A., SeilerP.Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog2010; 6: e1001022.
11.
SeibertC.W., KaminskiM., PhilippJ.Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol2010; 84: 11219–11226.
12.
KisoM., ShinyaK., ShimojimaM.Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog2010; 6: e1001079.
